Sugi Predict

Sugi Predict / Compounds / SCHEMBL17025824

SCHEMBL17025824

SCHEMBL17025824

CC(C)(C)OC(=O)n1ncc2cc(Nc3ccnc(Cl)n3)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 5/20 0.54
▸ ROCK1 Q13464 3/20 0.54
▸ CHEK2 O96017 1/20 0.54
▸ PRKACA P17612 1/20 0.54
▸ RPS6KA3 P51812 1/20 0.54
▸ PAK1 Q13153 1/20 0.54
▸ DYRK1A Q13627 1/20 0.54
▸ PRKD2 Q9BZL6 1/20 0.54
▸ EGFR P00533 1/20 0.50
▸ ITK Q08881 1/20 0.50
▸ EEF2K O00418 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ CLK2 P49760 1/20 0.49
▸ GSK3B P49841 1/20 0.49
▸ PRKX P51817 1/20 0.49
▸ NEK4 P51957 1/20 0.49
▸ PRKG2 Q13237 1/20 0.49
▸ PKN2 Q16513 1/20 0.49
▸ TAOK1 Q7L7X3 1/20 0.49
▸ AURKB Q96GD4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20612438 0.87 ROCK2 (0.55) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL20612328 0.86 ROCK2 (0.54) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL21341511 0.85 ROCK2 (0.54) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL17025789 0.84 CDC7 (0.48) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL20612437 0.84 EGFR (0.56) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL20617778 0.84 ROCK2 (0.56) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL24709490 0.83 ROCK2 (0.54) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL20611784 0.83 EGFR (0.65) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL15638401 0.83 ROCK2 (0.61) ROCK2ROCK1CHEK2PRKACARPS6KA3
SCHEMBL21100830 0.82 EGFR (0.41) ROCK2ROCK1CHEK2PRKACARPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034127-A1 TREATMENT OF GVHD KADMON CORP LLC (FR) 2026-02-05 — — US disclosed
EP-3647311-B1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-11-01 — — EP disclosed
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-02-02 — — US disclosed
EP-4116293-A2 RHO KINASE INHIBITORS Kadmon Corporation, LLC (US) 2023-01-11 — — EP disclosed
US-20220395501-A1 TREATMENT OF GVHD KADMON CORP LLC (US) 2022-12-15 — — US disclosed
US-20220395501-A1 TREATMENT OF GVHD KADMON CORP LLC (US) 2022-12-15 — — US disclosed
EP-3421465-B1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2022-10-26 — — EP disclosed
EP-2903618-B1 RHO KINASE INHIBITORS KADMON CORP LLC (US) 2022-06-01 — — EP disclosed
EP-2903618-B1 RHO KINASE INHIBITORS KADMON CORP LLC (US) 2022-06-01 — — EP disclosed
US-11311541-B2 Treatment of GVHD KADMON CORPORATION, LLC (US) 2022-04-26 — — US disclosed
US-20170112832-A1 TREATMENT OF GVHD KADMON CORPORATION, LLC 2017-04-27 — — US disclosed
US-20170112832-A1 TREATMENT OF GVHD KADMON CORPORATION, LLC 2017-04-27 — — US disclosed
US-20170112832-A1 TREATMENT OF GVHD KADMON CORPORATION, LLC 2017-04-27 — — US disclosed
WO-2015157556-A1 TREATMENT OF GVHD KADMON CORPORATION, LLC (US) 2015-10-15 — — WO disclosed
US-20150252025-A1 RHO KINASE INHIBITORS KADMON CORPORATION, LLC 2015-09-10 — — US disclosed
US-20150252025-A1 RHO KINASE INHIBITORS KADMON CORPORATION, LLC 2015-09-10 — — US disclosed
US-20150252025-A1 RHO KINASE INHIBITORS KADMON CORPORATION, LLC 2015-09-10 — — US disclosed
US-20150238601-A1 TREATMENT OF OCULAR DISORDERS KADMON CORPORATION, LLC 2015-08-27 — — US disclosed
US-20150238601-A1 TREATMENT OF OCULAR DISORDERS KADMON CORPORATION, LLC 2015-08-27 — — US disclosed
US-20150238601-A1 TREATMENT OF OCULAR DISORDERS KADMON CORPORATION, LLC 2015-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034127-A1 TREATMENT OF GVHD ROCK2, RHOA, MYH2 ROCK2 1/4885ROCK1 4/4885CHEK2 3404/4885
US-20170112832-A1 TREATMENT OF GVHD ROCK2, ROCK1, RHOA ROCK2 1/4885ROCK1 2/4885CHEK2 3192/4885
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF ROCK1, ROCK2, RHOA ROCK2 2/4885ROCK1 1/4885CHEK2 1981/4885
US-20150238601-A1 TREATMENT OF OCULAR DISORDERS ROCK2, KDR, FLT1 ROCK2 1/4885ROCK1 5/4885CHEK2 1994/4885
US-20220395501-A1 TREATMENT OF GVHD ROCK2, ROCK1, RHOXF2 ROCK2 1/4885ROCK1 2/4885CHEK2 3143/4885
US-11311541-B2 Treatment of GVHD ROCK2, ROCK1, RHOA ROCK2 1/4885ROCK1 2/4885CHEK2 3192/4885
US-20150252025-A1 RHO KINASE INHIBITORS ROCK2, ROCK1, RHOA ROCK2 1/4885ROCK1 2/4885CHEK2 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.